0001104659-26-018169
SEC filingAccendra Health, Inc. reported net revenue of $2.76 billion for fiscal year 2025, generating operating income of $27.5 million. However, the company recorded a significant net loss of $1.10 billion, primarily driven by a $998.0 million loss from discontinued operations. The continuing operations segment reported a loss of $102.7 million after tax, with interest expense of $107.2 million being a major contributing factor. The company's balance sheet shows total assets of $2.45 billion against total liabilities of $2.91 billion, resulting in a deficit equity position of -$461.0 million. Cash flow from operations was negative at -$101.8 million, while investing activities generated $144.4 million primarily from the P&HS sale proceeds of $342.4 million. The company ended the period with $282.0 million in cash and cash equivalents and total debt of $2.05 billion including current and long-term portions.
Accendra Health, Inc. reported fiscal year 2025 results with net revenue of $2.76 billion. The company achieved operating income of $27.5 million, calculated from total operating costs and expenses of $2.73 billion against the revenue base. However, significant interest expense of $107.2 million, transaction financing fees of $18.3 million, and other expenses resulted in a loss from continuing operations before income taxes of -$102.0 million. After a minimal income tax provision of $729K, the loss from continuing operations was -$102.7 million. The most substantial impact came from discontinued operations, which recorded a loss of -$998.0 million net of tax, leading to a total net loss of -$1.10 billion. Basic and diluted net loss per common share were both -$14, comprising -$1 from continuing operations and -$13 from discontinued operations.
The company reported net revenue of $2.76 billion for fiscal year 2025. The document does not provide segment breakdown, geographic mix, or specific growth drivers beyond the aggregate revenue figure. No comparative prior period revenue data is provided in the XBRL data or document text, preventing year-over-year growth analysis. The revenue figure represents the consolidated total for the company's continuing operations during the fiscal year.
Gross profit was $1.29 billion, calculated from net revenue of $2.76 billion minus cost of net revenue of $1.47 billion, resulting in a gross margin of 46.7%. Operating margin was 1.0% based on operating income of $27.5 million against revenue of $2.76 billion. The cost structure included selling, general and administrative expenses of $1.07 billion, transaction breakage fee of $80.0 million, acquisition-related charges and intangible amortization of $95.8 million, and exit and realignment charges of $18.4 million. No goodwill impairment charge was recorded for the period. The company's profitability was significantly impacted by high interest expense of $107.2 million and losses from discontinued operations.
Cash flow from operating activities was negative at -$101.8 million, driven by net loss of -$1.10 billion, partially offset by adjustments including depreciation and amortization of $214.5 million. Investing activities generated positive cash flow of $144.4 million, primarily from proceeds from P&HS sale of $342.4 million and proceeds from sale of patient service equipment of $78.0 million, partially offset by additions to patient service equipment of $191.0 million. Financing activities provided $188.1 million, with significant borrowing and repayment activity under credit facilities. The balance sheet shows total assets of $2.45 billion, including current assets of $547.9 million (with $282.0 million in cash and equivalents) and goodwill of $1.23 billion. Total liabilities were $2.91 billion, including total debt of $2.05 billion (current portion $250.0 million, long-term $1.80 billion), resulting in deficit equity of -$461.0 million.
The document content and XBRL data provided do not include management guidance, strategic priorities, or specific risk factors beyond the financial statements. No forward-looking statements, outlook commentary, or strategic initiatives are disclosed in the provided materials. The analysis is limited to the historical financial results for fiscal year 2025 as presented in the financial statements.